Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima? SC, for the treatment of people with rheumatoid arthriti
- Remsima? SC is the innovative subcutaneous (SC) version of Celltrion Healthcare's Remsima?
- This novel formulation provides an alternative administration option for Canadian physicians and their patients
- Celltrion Healthcare Canada Limited will continue to work to ensure access to innovative, high-quality biologics in?Canada?and around the world for patients with inflammatory conditions
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients' access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the U.S. FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit:?https://www.celltrionhealthcare.com/en-us